Cannabinoids showed limited benefit for chronic primary pain in short-term studies | Research

The takeaway

A meta-analysis of 8 randomized trials found cannabinoids did not significantly reduce chronic primary pain overall, but treatment lasting more than 4 weeks showed significant pain reduction.

Chronic pain patients and clinicians considering cannabinoid therapy.

Significant pain relief only after 4+ weeks of treatment

What the researchers found

Across 8 RCTs with 240 patients, VAS pain reduction was not significant for cannabinoids vs placebo (MD -0.64, CI -1.30 to 0.02). However, studies with more than 4 weeks of treatment showed significant pain reduction (MD -1.28, CI -2.33 to -0.22). No significant differences were found for fibromyalgia impact, anxiety, depression, or discontinuation due to adverse events.

Why it matters

Chronic primary pain (including fibromyalgia and other conditions) affects millions. This meta-analysis suggests cannabinoids may need longer treatment periods to show benefit.

The numbers in context

8 RCTs, 240 patients. Overall pain: MD -0.64, non-significant. Over 4 weeks: MD -1.28, significant. FIQ, anxiety, depression: non-significant. Evidence quality generally low.

How the study worked

Systematic review and meta-analysis searching PubMed, EMBASE, and Cochrane through October 2021. Included 8 RCTs (4 parallel, 4 crossover) with 240 chronic primary pain patients. Evidence quality assessed using GRADE.

What this study cannot tell us

Very small total sample (240 patients). Generally low-quality evidence due to imprecision and bias risk. Heterogeneous pain conditions grouped under "chronic primary pain."

How to read the evidence

Systematic meta-analysis, but very small sample sizes and generally low-quality underlying evidence.

When this study was published

Published in 2022 with studies searched through October 2021.

The bigger picture

The finding that longer treatment produced significant pain relief suggests cannabinoids may have a gradual onset of benefit for chronic primary pain, unlike acute analgesics.

Questions still open

What is the optimal treatment duration for cannabinoids in chronic pain? Would larger trials confirm the longer-term benefit signal?

Common questions

Do cannabinoids help chronic pain?

Overall results were not statistically significant, but studies lasting more than 4 weeks did show significant pain reduction, suggesting cannabinoids may need time to build therapeutic effects.

Why were the results inconclusive?

Only 240 patients across 8 small trials were available. The evidence quality was generally low, and most studies were too short to capture potential longer-term benefits.

Read the original research

Systematic Review and Meta-analysis Seem to Indicate that Cannabinoids for Chronic Primary Pain Treatment Have Limited Benefit.

Pain and therapy, 11(4), 1341-1358

View on PubMed ↗Publisher’s paper ↗

Citation

Giossi, Riccardo; Carrara, Federica; Padroni, Matteo; Bilancio, Maria Concetta; Mazzari, Martina; Enisci, Silvia; Romio, Maria Silvia; Boni, Gloria; Corrù, Federica; Fittipaldo, Veronica Andrea; Tramacere, Irene; Pani, Arianna; Scaglione, Francesco; Fornasari, Diego. (2022). Systematic Review and Meta-analysis Seem to Indicate that Cannabinoids for Chronic Primary Pain Treatment Have Limited Benefit.. Pain and therapy, 11(4), 1341-1358. https://doi.org/10.1007/s40122-022-00434-5